Bayer sells subsidiary in €1.2B deal

Bayer has struck a deal to sell its material sciences division, H.C. Starck, to a group of investors for €1.2 billion. Bayer had announced earlier that it was shopping the subsidiary to help cover the cost of acquiring Schering. Germany's H.C. Starck, which makes specialty chemicals and metal and chemical powders, will be positioned for a public offering in three to five years.

- see the press release
- read the Pittsburgh Business Journal report

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.